Results 91 to 100 of about 22,968 (195)
Patient-Derived Xenograft Models for Endometrial Cancer Research [PDF]
, 2018 Endometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations ...
Amant, Frederic +13 more
core +3 more sources
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related death worldwide. Cyclin‐dependent kinase 4 (CDK4) is a well‐validated oncogenic driver in NSCLC, yet current CDK4 inhibitors—predominantly based on the aminopyrimidine scaffold—are limited by structural homogeneity and the rapid emergence of acquired ...
Xinyu Chi +5 more
wiley +1 more source
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma [PDF]
, 2017 Malignant Mesothelioma (MM) is a rare and aggressive form of tumour that affects the lining of the internal organs for which current treatments have not been proven to be very effective.
Corona, Silvia P +3 more
core +1 more source
Drug Development Research, Volume 87, Issue 3, May 2026.ABSTRACT Osteosarcoma and rhabdomyosarcoma are the most common pediatric sarcomas, yet prognosis remains poor due to high relapse rates. This study investigates the repurposing of palbociclib (PB) and disulfiram (DS), alongside sodium selenite (SS), as potential therapeutic strategies.
María Ángeles Chico +6 more
wiley +1 more source
Genotoxic Damage Activates the AMPK-α1 Isoform in the Nucleus via Ca2+/CaMKK2 Signaling to Enhance Tumor Cell Survival [PDF]
, 2017 2017 American Association for Cancer Research. Many genotoxic cancer treatments activate AMP-activated protein kinase (AMPK), but the mechanisms of AMPK activation in response to DNA damage, and its downstream consequences, have been unclear.
Agbani, Ejaife O. +5 more
core +3 more sources
Breast Cancer Research, 2019 Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens.
Lorenzo Rossi +19 more
doaj +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.ABSTRACT Purpose This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real‐world data (RWD). Methods We conducted a scoping review of published, English‐language studies describing algorithms for identifying any LOTs with ...
Oluwadamilola Onasanya +19 more
wiley +1 more source
PLoS ONEBreast cancer (BC) cells have a high risk of metastasis due to epithelial-mesenchymal transition (EMT). Palbociclib (CDK4/6 inhibitor) is an approved drug for BC treatment.
Xiaogang Li +7 more
doaj +1 more source
Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. [PDF]
, 2019 Accessory male breast cancer (BC) is a rare entity and is associated with poor outcome. We report a 76-year-old patient who was diagnosed with concurrent accessory breast and primary lung cancer, both were positive for somatic BRCA-2 (E1593D) mutation ...
Cheng, Yu +4 more
core
Медицинский совет, 2019 Palbociclib is the first-in-class drug of CDK 4/6 inhibitors group. The use of palbociclib in combination with endocrinotherapy (ET) opens up new possibilities for the treatment of metastatic hormone receptor-positive (HRP+) HER2-negative (HER2-) breast ...
L. G. Zhukova +6 more
doaj +1 more source